Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Entire DC Network
Cellular Uptake Mechanism Of Paclitaxel Nanocrystals, Iris K. Archer, Zhaohui Wang, Tonglei Li
Cellular Uptake Mechanism Of Paclitaxel Nanocrystals, Iris K. Archer, Zhaohui Wang, Tonglei Li
The Summer Undergraduate Research Fellowship (SURF) Symposium
Therapeutic options for metastasized human cancer in current practice remain limited and, sadly, there is no cure for metastatic cancer. The typical approach, chemotherapy, has both low efficacy due to poor drug solubility, and cytotoxic side effects to healthy tissue when delivered indiscriminately. To address both of these issues, we are pursuing the use of nanocrystal formulations of current chemotherapeutic agents as delivery platforms. Herein, we have studied cellular uptake mechanisms in cancer cells of nanocrystals of a chemotherapeutic agent, paclitaxel. Our goal in this study is to determine whether the nanocrystals can be taken up via endocytosis, especially when …
Biomarkers For Vincristine-Induced Neuropathy, Danni Li, Jayachandran Devaraj, Doraiswami Ramkrishna
Biomarkers For Vincristine-Induced Neuropathy, Danni Li, Jayachandran Devaraj, Doraiswami Ramkrishna
The Summer Undergraduate Research Fellowship (SURF) Symposium
Vincristine is a vinca alkaloid, a commonly used chemotherapy drug for treating leukemia, lymphoma, multiple myeloma and some pediatric cancers. Its major dose-limiting side effect is peripheral neuropathy. The current dosing of “standard-dose-for-all” ignores the genetic and phenotypic variations among different patients, and causes severe neuropathy in some patients while ineffectively treats the others. In the present study, we aim to discover novel biomarkers involved in vincristine-induced neuropathy and identify patients with varied metabolic characteristics. Thus treatment can be tailored accordingly to improve outcomes of vincristine treatment. Pre-dose and post-dose serum samples were collected from two groups of patients (low …